Aka-Med Centrum Sp. z o.o. S.K.
- Address
- Ul. 1 Maja 323, 41-710 Ruda Śląska, Poland
Cardiovascular Disease Research
The clinical trial program at Aka-Med Centrum Sp. z o.o. S.K. focuses on cardiovascular diseases, with studies centered on conditions such as atherosclerotic cardiovascular disease, high cardiovascular risk, and related blood vessel disorders. These trials are designed to test new treatment approaches and measure whether they can reduce serious heart and stroke-related events.
- Studies in atherosclerotic cardiovascular disease and established vascular disease
- Research on lowering the risk of major adverse cardiovascular events
- Trials aimed at improving prevention for people with high cardiovascular risk
Overall, the site is contributing to research that evaluates whether emerging therapies can better protect patients from heart attacks, strokes, and other major complications of cardiovascular disease.
Lipid and Atherosclerosis-Related Studies
This research area includes trials for people with elevated lipoprotein(a) and persistent atherosclerotic heart and blood vessel disease. The studies are mainly exploring whether new therapies can improve lipid-related risk control and help prevent progression of atherosclerotic cardiovascular disease.
- Research targeting elevated lp(a) as a cardiovascular risk factor
- Studies in patients whose current lipid-lowering treatment is not enough
- Trials focused on reducing future heart attack and stroke risk
These trials reflect a strong interest in better long-term prevention for patients with cholesterol-related cardiovascular disease.
Heart Failure and Rhythm Disorder Research
The site also supports studies in heart failure and atrial fibrillation, including patients with heart failure with reduced ejection fraction and those with ongoing symptoms despite standard care. The purpose of this research is to assess whether new treatments can improve heart function, reduce hospital visits, and make care safer for patients with complex cardiac disease.
- Trials in heart failure and heart failure with reduced ejection fraction
- Studies for people with atrial fibrillation needing safer treatment options
- Research aimed at reducing hospitalization and urgent care needs
At this Ruda Slaska site, these studies help examine whether newer therapies can improve outcomes for patients living with chronic and high-risk heart conditions.
Kidney, Inflammation, and Blood Pressure-Related Research
Some of the trials combine cardiovascular disease with chronic kidney disease, systemic inflammation, and hypertension. This research is aimed at understanding how these overlapping conditions affect cardiovascular risk and whether newer treatments can better control blood pressure and reduce complications.
- Studies in patients with chronic kidney disease and systemic inflammation
- Research on hypertension that is not adequately controlled
- Trials evaluating prevention of cardiovascular death and heart-related events
These investigations support a broader effort to improve care for patients whose heart disease is complicated by kidney problems and persistent inflammatory risk.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Aka-Med Centrum Sp. z o.o. S.K.
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ziltivekimab | 2 | Unknown | 2021-09-24 | 2023-05-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.